Johnson & Johnson (JNJ) named one of the top 15 Dividend Stocks that Outperform the S&P 500. Barclays raises JNJ’s price target to $197 from $176, maintaining an Equal Weight rating. JNJ’s strong balance sheet allows for investments like the $3.05 billion acquisition of Halda Therapeutics to expand its oncology pipeline.

Strategically focused on high-margin categories, Johnson & Johnson’s Innovative Medicine unit thrives in oncology, immunology, and neuroscience. Its MedTech arm targets surgical robotics and digital surgery, with third-quarter net sales reaching $24 billion and net income surging 91% to $5.2 billion. JNJ operates across two core segments: Innovative Medicine and MedTech.

While JNJ shows investment potential, some believe AI stocks offer greater upside. For those looking for undervalued AI stocks, consider ones benefiting from Trump-era tariffs and onshoring trends. Explore the best short-term AI stock for potential investment opportunities.

Read more at Yahoo Finance: Barclays Raises Johnson & Johnson (JNJ) Price Target After Updated Estimates